Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma

• Status: Terminated
• Trial end date: 2015-04-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Vorinostat and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Bortezomib may also stop the growth of multiple myeloma by blocking blood flow to the tumor. Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving doxorubicin hydrochloride liposome together with vorinostat and bortezomib may kill more cancer cells.

PURPOSE: This phase I trial is studying the side effects and best dose of vorinostat and to see how well it works when given together with bortezomib and doxorubicin hydrochloride liposome in treating patients with relapsed or refractory multiple myeloma.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: UNC Lineberger Comprehensive Cancer Center
• Collaborators: Merck Sharp & Dohme Corp.; Millennium Pharmaceuticals, Inc.; National Cancer Institute (NCI); Ortho Biotech, Inc.
• Treatments: Bortezomib; Doxorubicin; Liposomal doxorubicin; Vorinostat

Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of multiple myeloma

• Relapsed or refractory disease

PATIENT CHARACTERISTICS:

• ECOG performance status 0-2

• Life expectancy ≥ 3 months

• ANC ≥ 1.0 x 10^9/L (no granulocyte growth factor support, e.g., G-CSF or GM-CSF allowed)

• Platelet count ≥ 100 x 10^9/L (erythropoietin allowed, no platelet or RBC transfusion within the past 2 weeks)

• Hemoglobin ≥ 8 g/dL (erythropoietin allowed, no platelet or RBC transfusion within the past 2 weeks)

• Creatinine clearance ≥ 30 mL/min

• AST or ALT ≤ 2.5 times upper limit of normal (ULN)

• Total bilirubin ≤ 1.5 times ULN

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception during and for 3 months after completion of study treatment

• LVEF ≥ 45% by MUGA or ECHO

• Symptomatic neuropathy < grade 2

• No known history of HIV

• No active or serious infection, medical or psychiatric illness that would preclude study participation

• No active hepatitis B or C infection

• No other prior or concurrent malignancy except for adequately treated basal cell or squamous cell carcinoma of the skin, in situ malignancy, low-risk prostate cancer after curative therapy, or other cancer for which the patient has been disease-free for ≥ 3 years

• No history of hypersensitivity reaction to bortezomib or any of its components (boron, mannitol), vorinostat, doxorubicin hydrochloride, or any of the components of PLD

• No serum potassium ≤ 3.0 or serum magnesium ≤ 1.6 that cannot be corrected with supplementation are excluded

• Patients must have adequate cardiovascular function, defined by all of the following:

• No EKG evidence of active, clinically significant conduction system abnormalities

• No EKG evidence of QTc prolongation > grade 2

• NOTE: Any EKG abnormality at screening has to be documented by the investigator as not medically significant.

PRIOR CONCURRENT THERAPY:

• No limit to number of prior treatment regimens

• At least 30 days since prior therapy and recovered

• At least 3 months since prior autologous stem cell transplantation and recovered

• Prior allogeneic stem cell or bone marrow transplantation allowed provided the following criteria are met:

• More than 1 year since transplantation

• No longer receiving immunosuppressive therapy or treatment for graft-versus-host disease (GVHD) prophylaxis

• No active GVHD

• No active, uncontrolled infections

• No major surgery within the past 3 weeks

• No prior anthracycline dose > 360 mg/m^2 for doxorubicin hydrochloride (including pegylated liposomal doxorubicin hydrochloride [PLD]) or 720 mg/m^2 for epirubicin hydrochloride

• No prior or concurrent histone deacetylase inhibitor (e.g., valproic acid)

• No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF) during course 1

• No other concurrent investigational or anticancer agent